1. Market Research
  2. > Meda AB - Product Pipeline Review - 2013

Meda AB - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 24 pages

Meda AB - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Meda AB - Product Pipeline Review - 2013” provides data on the Meda AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Meda AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Meda AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Meda AB - Brief Meda AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Meda AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Meda AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Meda AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Meda AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Meda AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Meda AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Meda AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Meda AB and identify potential opportunities in those areas.

Table Of Contents

Meda AB - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Meda AB Snapshot 4
Meda AB Overview 4
Key Information 4
Key Facts 4
Meda AB - Research and Development Overview 5
Key Therapeutic Areas 5
Meda AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Meda AB Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Meda AB - Drug Profiles 11
Dexpirronium 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
flupirtine maleate 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Onsolis 13
Product Description 13
Mechanism of Action 13
sotirimod 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Meda AB - Pipeline Analysis 15
Meda AB - Pipeline Products by Therapeutic Class 15
Meda AB - Pipeline Products By Target 16
Meda AB - Pipeline Products By Mechanism of Action 17
Meda AB - Recent Pipeline Updates 18
Meda AB - Dormant Projects 20
Meda AB - Company Statement 21
Meda AB - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables

Meda AB, Key Information 4
Meda AB, Key Facts 4
Meda AB - Pipeline by Indication, 2013 6
Meda AB - Pipeline by Stage of Development, 2013 7
Meda AB - Monotherapy Products in Pipeline, 2013 8
Meda AB - Phase II, 2013 9
Meda AB - Phase I, 2013 10
Meda AB - Pipeline By Therapeutic Class, 2013 15
Meda AB - Pipeline By Target, 2013 16
Meda AB - Pipeline Products By Mechanism of Action, 2013 17
Meda AB - Recent Pipeline Updates, 2013 18
Meda AB - Dormant Developmental Projects,2013 20
Meda AB, Subsidiaries 22

List of Figures

Meda AB - Pipeline by Indication, 2013 6
Meda AB - Pipeline by Stage of Development, 2013 7
Meda AB - Monotherapy Products in Pipeline, 2013 8
Meda AB - Pipeline By Therapeutic Class, 2013 15
Meda AB - Pipeline Products By Mechanism of Action, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.